Wellington Management Group LLP trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,363,434 shares of the company's stock after selling 10,724,038 shares during the period. Wellington Management Group LLP owned 3.58% of Kenvue worth $1,459,559,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in KVUE. Grove Bank & Trust lifted its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Kenvue in the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. grew its holdings in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC increased its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after acquiring an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors.
Kenvue Trading Down 0.7 %
KVUE stock traded down $0.17 during midday trading on Thursday, hitting $23.71. 15,703,942 shares of the company's stock were exchanged, compared to its average volume of 16,740,610. The business has a 50-day simple moving average of $22.50 and a two-hundred day simple moving average of $22.47. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.31 billion, a PE ratio of 44.62, a P/E/G ratio of 2.62 and a beta of 1.25.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.46%. Kenvue's dividend payout ratio is currently 154.72%.
Analyst Ratings Changes
A number of brokerages have recently commented on KVUE. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Barclays increased their price objective on Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research report on Thursday, March 27th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. UBS Group lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $24.00.
View Our Latest Research Report on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
